SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of metabolic and liver diseases by targeting the liver and liver pathways, announced that yesterday it presented results from a preclinical study with MB07811 at the 234th National Meeting of the American Chemical Society in Boston, MA.
